期刊文献+

老年冠心病患者经皮冠状动脉介入治疗术后12个月临床疗效的性别差异 被引量:13

The effect of gender differences on long-term clinical outcomes among elderly patients treated with percutaneous coronary intervention
下载PDF
导出
摘要 目的观察老年冠心病患者行经皮冠脉介入治疗术后12个月缺血及出血事件的发生情况,分析其性别差异。方法本研究对1 423例经皮冠状动脉介入治疗的老年患者进行I LOVE IT 2的老年亚组分析,其中老年女性患者583例,老年男性患者840例。主要终点为靶血管失败(TLF),定义为心性死亡、心肌梗死或靶病变血运重建。结果 12个月随访时,两组患者TLF发生率分别为老年女性组6.35%,老年男性组6.19%,差异无统计学意义(P〉0.05),但老年女性患者发生BARC出血(bleeding academic research consortium,BARC)(1-5级)的风险较老年男性患者显著增高(7.72%vs 4.52%;P=0.01)。多因素分析结果提示,老年女性是PCI术后出血并发症发生的独立危险因素(HR=1.84,95%CI:1.19-2.84,P=0.006)。结论老年女性与老年男性相比,PCI术后TLF发生率无明显差异,但出血风险显著高于老年男性。 Objective To explore the effect of gender differences on the occurrence of ischemic and bleeding events among elderly patients with coronary artery disease 1 year after undergoing percutaneous coronary intervention(PCI). Methods As a subgroup analysis of the I-LOVE-IT2 trial, 1 423 elderly patients(women 583,men 840) with coronary artery disease treated with PCI were analyzed. Primary endpoint was target lesion failure(TLF),defined as a composite of cardiac death,myocardial infarction and target lesion revascularization. Results The incidences of TLF were comparable for women and men at 1 year follow-up(6.35%vs 6.19%,P = 0.90). Nevertheless,compared with men,the risk for bleeding at 1 year was significantly higher in elderly female(7.72% vs 4.52%; P = 0.01). Cox regression analysis showed that being an elderly woman was an independent predictor of bleeding.Conclusion There are no differences by sex for TLF after PCI in elderly patients,but the risk of bleeding is significantly higher in female than in male 1 year after PCI.
出处 《中华保健医学杂志》 2016年第5期352-355,共4页 Chinese Journal of Health Care and Medicine
基金 辽宁省科技攻关项目(2013225089) 军队临床高新技术重大项目(2010gxjs001)
关键词 老年女性 冠状动脉介入治疗 缺血事件 出血 Elderly female Percutaneous coronary intervention Ischemic events Bleeding
  • 相关文献

参考文献1

二级参考文献34

  • 1Lenzen M J, Boersma E, Bertrand ME, Maier W, Moris C, Piscione F, et al, on behalf of European Society of Cardiology. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. Eur Heart J 2005; 26: 1169-1179.
  • 2Kelsey SF, James M, Holubkov AL, Holubkov R, Cowley M J, Detre KM. Results of percutaneous transluminal coronary angioplasty in women. 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. Circulation 1993; 87: 720-727.
  • 3Malenka D J, O'Connor GT, Quinton H, Wennberg D, Robb JF, Shubrooks S, et al. Differences in outcomes between women and men associated with percutaneous transluminal coronary angioplasty. A regional prospective study of 13 061 procedures. Northern New England Cardiovascular Disease Study Group. Circulation 1996; 94 (9 Suppl): I199-I104.
  • 4Jacobs AK, Kelsey SF, Yeh W, Holmes DR Jr, Block PC, Cowley M J, et al. Documentation of decline in morbidity in women undergoing coronary angioplasty (a report from the 1993-94 NHLBI Percutaneous Transluminal Coronary Angioplasty Registry). National Heart, Lung, and Blood Institute. Am J Cardiol 1997; 80: 979-984.
  • 5Jacobs AK, Kelsey SF, Brooks MM, Faxon DP, Chaitman BR, Bittner V, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1998; 98: 1279-1285.
  • 6Onuma Y, Kukreja N, Daemen J, Garcia-Garcia HM, Gonzalo N, Cheng JM, et al, Interventional Cardiologists of Thoraxcenter. Impact of sex on 3-year outcome after percutaneous coronary intervention using bare-metal and drug-eluting stents in previously untreated coronary artery disease: insights from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries. JACC Cardiovasc lnterv 2009; 2: 603-610.
  • 7Duvernoy CS, Smith DE, Kline-Rogers E, Share D, et al Manohar P, Schaefer A, Gender differences in adverse outcomes after contemporary percutaneous coronary intervention: an analysis from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) percutaneous coronary intervention registry. Am Heart J 2010; 159: 677-683.
  • 8Han YL, Zhang L, Yang LX, Liu HL, Qu P, Li WM, et al. A new generation of biodegradable polymer-coated sirolimus-eluting stents for the treatment of coronary artery disease: final 5-year clinical outcomes from the CREATE study. Eurolntervention 2012; 8: 815-822.
  • 9Han Y, Jing Q, Li Y, Yang L, Liu H, Shang X, et al. Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in "real-world" practice: three-year outcomes of the CREATE (Multi-Center Registry of EXCEL Biodegradable Polymer Drug Eluting Stents) study. Catheter Cardiovasc Interv 2012; 79:211-216.
  • 10Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv 2009; 2: 303-309.

共引文献6

同被引文献88

引证文献13

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部